Skip to main content

Table 4 Univariate and multivariate analyses of characteristics for completion time in clinical trials related to hip fractures

From: Characteristics of clinical trials related to hip fractures and factors associated with completion

Characteristics

Completion time (median, days)

Simple Cox regression

Multiple Cox regression

Multiple Cox regressiona

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Outcome measures including mortality

 Yes

1430.00

0.66 (0.52–0.84)

 < 0.01

0.89 (0.67–1.17)

0.40

0.83 (0.57–1.22)

0.34

 No

823.00

Gender

 Male

122.00

1.42 (0.89–2.26)

0.13

1.05 (0.67–1.66)

0.83

0.87 (0.47–1.64)

0.67

 Female

1065.00

 Both

931.00

Age including children

 Yes

882.00

0.97 (0.70–1.34)

0.84

1.00 (0.70–1.43)

1.00

0.83 (0.52–1.34)

0.45

 No

945.00

Age including older adults

 Yes

931.00

1.00 (0.51–1.93)

0.99

1.56 (0.74–3.27)

0.24

0.87 (0.24–3.18)

0.83

 No

1096.00

Phases

 Not applicable

973.00

1.09 (1.03–1.16)

 < 0.01

1.06 (0.98–1.14)

0.16

1.07 (0.96–1.19)

0.22

 Phase 1

360.00

 Phase 2

1055.00

 Phase 3

1036.00

 Phase 4

731.00

Enrollment

  ≤ 50

671.00

0.76 (0.71–0.82)

 < 0.01

0.77 (0.70–0.84)

 < 0.01

0.80 (0.71–0.90)

 < 0.01

  > 50 and ≤ 100

725.00

  > 100 and ≤ 200

1096.00

  > 200 and ≤ 400

1308.00

  > 400

1646.00

Funded by the NIH

 Yes

2007.00

0.44 (0.27–0.70)

 < 0.01

0.47 (0.28–0.82)

0.01

0.41 (0.22–0.78)

0.01

 No

894.00

Funded by industry

 Yes

762.00

0.88 (0.69–1.14)

0.33

0.96 (0.72–1.28)

0.79

1.09 (0.74–1.60)

0.66

 No

945.00

Allocation

 Not applicable

700.00

0.92 (0.80–1.06)

0.27

0.92 (0.72–1.18)

0.52

0.91 (0.65–1.28)

0.59

 Non-randomized

851.00

 Randomized

1003.00

  

Intervention model

 Single

819.00

1.01 (0.91–1.13)

0.83

1.13 (0.95–1.35)

0.16

1.18 (0.93–1.49)

0.18

 Sequential

744.00

 Parallel

1004.00

 Factorial

1065.00

 Crossover

365.00

Masking

 None

941.00

1.09 (1.01–1.17)

0.02

1.00 (0.92–1.10)

0.93

0.98 (0.87–1.11)

0.75

 Single

1037.00

 Double

819.00

 Triple

671.00

 Quadruple

1055.00

Primary purpose

 Diagnostic

  Yes

638.00

1.78 (1.08–2.94)

0.04

1.35 (0.66–2.74)

0.41

1.73 (0.60–5.00)

0.31

  No

950.00

 Health service research

  Yes

950.00

0.98 (0.56–1.70)

0.94

0.81 (0.39–1.70)

0.58

0.62 (0.20–1.89)

0.40

  No

931.00

 Prevention

  Yes

822.00

1.08 (0.85–1.39)

0.53

1.01 (0.59–1.71)

0.98

0.94 (0.44–2.01)

0.88

  No

1003.00

 Supportive care

  Yes

747.00

1.24 (0.84–1.83)

0.30

1.10 (0.60–2.02)

0.76

0.88 (0.38–2.04)

0.77

  No

945.00

 Treatment

  Yes

1047.00

0.83 (0.68–1.01)

0.06

0.76 (0.46–1.24)

0.26

0.75 (0.37–1.52)

0.42

  No

762.00

Interventions

 Behavioral

  Yes

882.00

0.96 (0.68–1.37)

0.83

1.16 (0.78–1.72)

0.46

0.95 (0.58–1.55)

0.82

  No

941.00

 Drug/biological

  Yes

731.00

1.57 (1.28–1.92)

 < 0.01

1.48 (1.07–2.05)

0.02

1.50 (0.96–2.35)

0.07

  No

1035.00

 Device

  Yes

1096.00

0.71 (0.58–0.88)

 < 0.01

0.93 (0.70–1.24)

0.63

0.91 (0.60–1.40)

0.68

  No

866.00

 Procedure

  Yes

914.00

0.98 (0.80–1.20)

0.83

1.07 (0.82–1.40)

0.60

0.75 (0.50–1.14)

0.17

  No

931.00

 Location in China

  Yes

866.00

1.25 (0.92–1.71)

0.17

0.93 (0.64–1.34)

0.68

0.56 (0.28–1.10)

0.09

  No

973.00

 Location in the United States

  Yes

1125.00

0.79 (0.63–0.99)

0.03

0.63 (0.46–0.87)

 < 0.01

0.56 (0.35–0.90)

0.02

  No

882.00

 Location in Europe

  Yes

1065.00

0.82 (0.68–0.98)

0.03

0.62 (0.48–0.81)

 < 0.01

0.51 (0.35–0.76)

 < 0.01

  No

821.00

 Location in Canada

  Yes

931.00

1.09 (0.75–1.57)

0.66

0.69 (0.45–1.05)

0.08

0.54 (0.30–0.97)

0.04

  No

945.00

  1. NIH National Institutes of Health, HR Hazard ratio, CI Confidence intervals
  2. aindicates P values obtained from the analysis excluding estimated completion time